Tag Archives: ophthalmology

Age-related Macular Degeneration (AMD)

June 27, 2024 by Modulight Content
No comments
Age-related Macular Degeneration (AMD) Age-related Macular Degeneration (AMD) is a disease causing choroidal neovascularization (CNV) and consequent irreversible damage in the macula. AMD is classified into dry (atrophic) and wet (exudative) forms, with the latter causing faster vision loss and being the leading cause of blindness in people over 65. Introduction to AMD Age-related Macular Degeneration (AMD) is one of the leading causes for  visual impairment. AMD is charactirized by development of Choroidal neovascularization (CNV) and consequent irreversible damage in the macula. CNV means abnormal Continue reading →

Novel ophthalmic PDT laser platform to target oncology and various other retinal indications

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.   Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to Continue reading →

Ophthalmic laser platform utilizing AI to enhance treatment planning of liposomal drug release

March 7, 2022 by Modulight
No comments
Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)   Delivery of pharmaceuticals to the eye posterior poses a major challenge in ophthalmology. A promising drug delivery platform is indocyanine green (ICG) liposomes, which absorb near-infrared light resulting in a release of pharmaceutical molecules. The Modulight ophthalmic laser platform has been designed for treatments targeting the eye posterior and can also excite the absorption band of the liposomes. The laser connects with Modulight Cloud, enabling Continue reading →

Protected: Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
There is no excerpt because this is a protected post.Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →

New Insights on Management of CSCR

May 1, 2021 by Modulight
No comments
Retinal Physician – May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight.Retinal Physician - May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight. Read article

Modulight becomes exclusive supplier for BAUSCH + LOMB

December 4, 2018 by Seppo Orsila
No comments
BRIDGEWATER, N.J., December 04, 2018 – Bausch + Lomb, a leading global eye health company, and Modulight, Inc., a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new photodynamic laser specifically designed for use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) therapy. “Photodynamic therapy continues to be an important option for eye care professionals who treat choroidal neovascularization in patients who suffer from persistent disease activity, but the availability of lasers capable Continue reading →

An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

February 1, 2018 by Modulight
No comments
Published in: Molecular Cancer Therapeutics Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller    Published in: Molecular Cancer Therapeutics Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller   The research group studied a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. Laser was used for evaluating tumor-specific targeting and cellular toxicity of their novel IRDye 700DX-conjugated papillomavirus-like particle (AU-011) in vitro Continue reading →